Comparative safety of Epirubicin and cyclophosphamide versus Docetaxel and cyclophosphamide in lymph node negative, HR-positive, HER2-negative breast cancer (ELEGANT): A randomized trial

被引：0
|
作者：
Liu, D. [1 ]
Zhu, L. [1 ]
Wu, J. [1 ]
机构：
[1] Ruijin Hosp, Dept Gen Surg, Comprehens Breast Hlth Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197P
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [1] The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
    Liu, Deyue
    Wu, Jiayi
    Lin, Caijin
    Ding, Shuning
    Lu, Shuangshuang
    Fang, Yan
    Huang, Jiahui
    Hong, Jin
    Gao, Weiqi
    Zhu, Siji
    Chen, Xiaosong
    Huang, Ou
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    Zhu, Li
    [J]. CANCERS, 2022, 14 (13)
  • [2] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [3] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [4] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wu, Wei
    Chen, Jiewen
    Deng, Heran
    Jin, Liang
    He, Zhanghai
    Rao, Nanyan
    Nie, Yan
    Yao, Yandan
    Yang, Yaping
    Su, Fengxi
    Liu, Jieqiong
    [J]. BMC CANCER, 2021, 21 (01)
  • [5] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wei Wu
    Jiewen Chen
    Heran Deng
    Liang Jin
    Zhanghai He
    Nanyan Rao
    Yan Nie
    Yandan Yao
    Yaping Yang
    Fengxi Su
    Jieqiong Liu
    [J]. BMC Cancer, 21
  • [6] West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
    Nitz, Ulrike
    Gluz, Oleg
    Clemens, Michael
    Malter, Wolfram
    Reimer, Toralf
    Nuding, Benno
    Aktas, Bahriye
    Stefek, Andrea
    Pollmanns, Anke
    Lorenz-Salehi, Fatemeh
    Uleer, Christoph
    Krabisch, Petra
    Kuemmel, Sherko
    Liedtke, Cornelia
    Shak, Steven
    Wuerstlein, Rachel
    Christgen, Matthias
    Kates, Ronald E.
    Kreipe, Hans H.
    Harbeck, Nadia
    Ackermann, S.
    Aktas, B.
    Augustin, D.
    Baake, G.
    Baumann, K.
    Berger, R.
    Bettscheider, J.
    Bischoff, J.
    Clemens, M.
    Deryal, M.
    Dubbers, H.
    Duchting, D.
    Dunnebacke, J.
    Fett, W.
    Fietz, T.
    Fischer, H.
    Forner, M.
    Forstbauer, H.
    Freese, K.
    Geberth, M.
    Glados, M.
    Gnauert, K.
    Goette, O.
    Gohring, U.
    Goppinger, A.
    Grafe, A.
    Hackenberg, R.
    Hackmann, J.
    Hellriegel, M.
    Heyl, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (10) : 799 - +
  • [7] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    [J]. Breast Cancer, 2017, 24 : 63 - 68
  • [8] Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
    Yang Yang
    Yingjian He
    Zhaoqing Fan
    Xue Chen
    Yiqiang Liu
    Chao Zhang
    Hongchuan Jiang
    Xin Wang
    Xiang Wang
    Fei Xie
    Shu Wang
    Bin Luo
    Hua Kang
    Tao Wang
    Zefei Jiang
    Peng Yuan
    Binhe Xu
    Ling Xu
    Yinhua Liu
    Jinfeng Li
    Yuntao Xie
    Tianfeng Wang
    Tao Ouyang
    [J]. npj Breast Cancer, 9
  • [9] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    [J]. BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [10] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
12345